Last $2.48 USD
Change Today -0.01 / -0.40%
Volume 12.5K
AXGN On Other Exchanges
As of 8:10 PM 07/10/14 All times are local (Market data is delayed by at least 15 minutes).

axogen inc (AXGN) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/31/13 - $5.20
52 Week Low
06/3/14 - $2.21
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for AXOGEN INC (AXGN)

Related News

No related news articles were found.

axogen inc (AXGN) Related Businessweek News

No Related Businessweek News Found

axogen inc (AXGN) Details

AxoGen, Inc. operates as a medical technology company. It focuses on advancing the science and commercialization of peripheral nerve repair solutions. It offers a range of surgical nerve repair solutions, including Avance Nerve Graft, a processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa ExtraCellular Matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce coaptation sites while preventing soft tissue attachments. The company’s products are used by plastic reconstructive surgeons, and orthopedic and plastic surgeons during surgical interventions to repair various nerve injuries. It procures and processes its tissue products in the United States, Canada, Italy, Austria, the United Kingdom, the Netherlands, Israel, and Switzerland. AxoGen, Inc. is headquartered in Alachua, Florida.

73 Employees
Last Reported Date: 03/6/14

axogen inc (AXGN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $314.5K
Co-Founder and Vice President
Total Annual Compensation: $183.6K
Senior Vice President of Business Development...
Total Annual Compensation: $251.6K
Senior Vice President of Sales
Total Annual Compensation: $314.6K
Senior Vice President of Business Strategy & ...
Total Annual Compensation: $231.1K
Compensation as of Fiscal Year 2013.

axogen inc (AXGN) Key Developments

AxoGen, Inc. Presents at JMP Securities Healthcare Conference, Jun-24-2014 12:30 PM

AxoGen, Inc. Presents at JMP Securities Healthcare Conference, Jun-24-2014 12:30 PM. Venue: The Westin New York Grand Central, 212 East 42nd Street, New York, NY 10017, United States.

AxoGen Announces Executive Changes

AxoGen, Inc. announced the appointment of Lee Robert Johnston, Jr. as Chief Financial Officer, effective May 12, 2014. Mr. Johnston will report directly to Karen Zaderej, President and Chief Executive Officer. Gregory Freitag, who previously held the position of Chief Financial Officer and General Counsel, will transition to the role of General Counsel and Senior Vice President of Business Development. Additionally, Mr. Freitag will continue to serve on the Company’s Board of Directors. With 20 years of financial and operational experience in the healthcare sector, Mr. Johnston will be responsible for AxoGen’s global finance and administrative functions, including financial planning and analysis, tax, investor relations, and human resources. Prior to joining AxoGen, he was the SVP of Corporate Development and CFO of Scientific Protein Laboratories, LLC, a pharmaceutical company recently acquired by Hepalink.

AxoGen, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014

AxoGen, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2014. For the period, the company reported revenues of $3,138,256 against $2,142,932 a year ago. Loss from operations was $2,991,142 against $2,323,554 a year ago. Net loss available to common shareholders was $4,239,564 against $3,437,508 a year ago. Basic and diluted loss per common share was $0.24 against $0.31 a year ago. Net cash used for operating activities was $3,150,593 against $2,651,186 a year ago. Purchase of property and equipment was $195,482 against $26,007 a year ago. Acquisition of intangible assets was $8,346 against $31,415 a year ago. Revenue for the 2014 first quarter increased 46% to $3.14 million compared to $2.14 million for the first quarter of 2013, reflecting sales to new accounts and increased product usage by existing accounts.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AXGN:US $2.48 USD -0.01

AXGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $76.75 USD +0.93
Integra LifeSciences Holdings Corp $46.33 USD +0.15
Stryker Corp $83.68 USD -0.30
View Industry Companies

Industry Analysis


Industry Average

Valuation AXGN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.6x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AXOGEN INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at